Preferred Label : Mavorixafor;
NCIt synonyms : (S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine;
NCIt definition : An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with
potential antineoplastic and immune checkpoint inhibitory activities. Upon administration,
mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand,
stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation
and results in decreased proliferation and migration of CXCR4-overexpressing tumor
cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T-cells
and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby
abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic
T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled
receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment
of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance,
and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor
for HIV entry into T-cells.;
UNII : 0G9LGB5O2W;
InChIKey : WVLHHLRVNDMIAR-IBGZPJMESA-N;
CAS number : 558447-26-0;
Molecule name : AMD-11070; X4P-001; AMD-070; X4P 001;
Origin ID : C126660;
UMLS CUI : C2930725;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
